Case Study: Amgen achieves 20% more patients per site and faster enrollment with OneStudyTeam's StudyTeam

Amgen Increases Efficiencies in Working with Sites and Improves Enrollment Across Its Global Research Portfolio

Amgen, one of the world’s largest independent biopharmaceutical companies, faced fragmented, manual pre‑screening and enrollment workflows (emails, faxes, spreadsheets) that limited real‑time visibility and delayed enrollment decisions. To address these challenges, Amgen partnered with OneStudyTeam and deployed the StudyTeam platform to centralize pre‑screening activity and streamline sponsor–site collaboration.

OneStudyTeam’s StudyTeam was rolled out across 26 clinical trials (15 products/indications) in 20 countries and 1,000+ research sites, giving Amgen portfolio‑wide enrollment visibility and earlier site engagement. Use of StudyTeam helped Amgen reduce average enrollment time by 25 days per trial and non‑enrollment by 25%, and sites using StudyTeam enrolled 20% more patients per site per month, were 60% less likely to be zero‑enrollers, and 86% of sites preferred StudyTeam over other methods.

Amgen

Dylan Rosser

Executive Director of Global Development Operations